Trade name : Evergraf
Active component : Everolimus
Strength : 0.25mg
Manufactured by : Panacea Biotech Ltd
Pack : 10 tablets in a strip


Evergraf 0.25mg is belongs to class of anti-cancer drugs
Evergraf 0.25mg contains of an active compound known as Everolimus which is interfere with development of cancer cell and process is slows down.
Evergraf 0.25mg tablets is not a curable medication, which is helps to slow their spreading into the body.


The drug Evergraf 0.25mg is mainly used for the treatment of following disease
• kidney carcinoma
• Breast carcinoma
• Brain carcinoma
Evergraf 0.25mg is also used to treat in various advanced stage cancer in stomach, intestines or pancreas.


Everolimus is a prohibitor of mTOR, links at peak compatibility to FK506 binding protein 12, through producing drug complex which prevents the productive of mTOR. This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, finally causes cell growth arrest and apoptosis.Evergrafalso prohibits the expression of hypoxia-inducible factor, causing to a reduces in the expression of vascular endothelial growth factor. The results of everolimus prevention of mTOR is a reduction in cell multiplication, angiogenesis, and glucose uptake.


The time to peak plasma concentration of Evergraf 0.25mg occurs between 1 to 2 hours.
The drug Evergraf 0.25mg has Albumin human plasma protein bound of 74%.
In hepatic Evergraf 0.25mg metabolism is take place, which is a substrate of CYP3A4.
The Evergraf 0.25mg metabolism will occur through 3 processes;
• Three monohydroxylated metabolite,
• Two hydrolytic rings opened products,
• Phosphatidylcholine conjugate of Everolimus.
The drug excretion primarily through 5% in urine; the parent compound has been detected in urine or feces.
The drug half-life period is 30 hours


Evergraf tablets should be given with or without food
. Dosage regimen of Evergraf:
In breast cancer, renal cell cancer, pancreatic cancer, Neuro endocrine cancer:
The prescribed dosage is 10mg should be taken as a single dose.
In Brain or intracranial cancer:
The prescribed dosage of Evergraf as a single dose. is 4.5mg/m2 given orally
In pediatric:
The pediatric dosage of Evergraf as a single dose in brain or intracranial tumor is 4.5mg/m2 should be given orally.


Embryo fetal toxicity:
using Evergraf 0.25mg in pregnancy condition Causes fetal damage
Developed hazard of skin cancers, patient may protect from UV light
Serious infections:
Patients getting Evergraf 0.25mg have severe risk of achieve various infections related to bacteria, virus, and fungi.
Hepatic artery thrombosis:
Evergraf 0.25mg therapy should not be recommended in in liver transplant patients.
Hereditary disorders:
while using Evergraf the conditions occurs like galactose intolerance, glucose-galactose malabsorption, Evergraf 0.25mg should not be used may results in diarrhea & malabsorption.
Grape juice interaction:
avoid these concomitant use with grape juice Causes increasing blood levels of Everolimus
While using Evergraf 0.25mg in renal impaired patients Renal function should be monitored frequently; drug use with caution
While patients receiving concomitantly Evergraf 0.25mg with Angiotensin converting enzyme agents will cause angioedema
Interstitial lung disease:
In Evergraf 0.25mg therapy interstitial lung disease occur
Blood glucose level should be monitored

Drug – Drug interaction

Interaction of Evergraf 0.25mg with strong inhibitor of CYP3A4, or P-gp, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus.
Concomitant use of Evergraf 0.25mg with strong CYP3A4 inducers, will increasing the disclosure of Everolimus.
Interaction of Evergraf 0.25mg with cyclosporine will increasing the AUC level of Everolimus frequently.
Interaction of ketoconazole with Evergraf 0.25mg tablet or other CYP3A4 inhibitors will increasing the plasma concentration and AUC of Everolimus.
Combination of Evergraf 0.25mg with verapamil leads to increasing the plasma concentration of Everolimus.
Interaction of Evergraf 0.25mg with Atorvastatin or pravastatin leads to rhabdomyolysis, due to increasing concentration of lipid lowering agents.
When Evergraf 0.25mg combination with rifampicin will reduces the AUC of Everolimus


The over dosage of Everolimus is limited, If over dosage occurs patient must be provide with supportive measures. And monitor evidence of toxicity in Everolimus over dosage


If the patients missed dose, patients must consult with medical practitioner and follow the instructions given by them.
Or missed dose should be avoid and follow the regular dosing schedule.


• Nephrotoxicity
• Thrombocytopenia
• Hypersensitivity reactions
• Hyperlipemia
• Angioedema
• Lymphomas & other malignancy
• Male infertility
• Proteinuria
• New commencement of diabetes
• Serious infections
• Kidney graft thrombosis
• Hepatic artery thrombosis
• Interstitial lung disease.

We'd Like to Hear From You!


1., a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.
2. will not dispense any prescription medication without a valid prescription from a licensed physician.
3. If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.
4. The drug information provided in the is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.
5. requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from
6. At, a Caregiver can order prescription medicines on your behalf.

This information should not be used to decide whether to accept this product or any other medicine. Only a health care provider is knowledge and training to decide that a medicine suitable for a specific patient. This information does not support any drug as safe, are effective or approved for the treatment of any patient or health condition. It's simple a brief overview of general information about this product. It does not include all information on possible applications, indications, warnings, precautions, interactions, adverse effects or risks that may be relevant to this product. This information is not specific medical advice and does not replace information obtained from your health care provider. You should check with your health care provider for complete information about the risks and benefits of using this product.